PROGRAM DAY 2: Tuesday, November 10th 2020

(All times shown as Eastern Standard Time, EST)

08:00 – 09:15Session V: Gene and Base Editing of/with mRNAChair: Melissa Moore
08:00 – 08:25Spatial and environmental tuning of genetic information within the cephalopod nervous system by RNA editingJoshua Rosenthal (MBL Woods Hole)
08:25 – 08:50Base Editing and Prime Editing: Chemistry on the Genome Editing Without Double-Strand BreaksDavid Liu (Harvard Chemistry)
08:50 – 09:15Selective ORgan Targeting (SORT): A strategy for effective tissue specific mRNA delivery and gene editingDan Siegwart (UTSW)
09:15 – 09:30Break 
09:30 – 11:05Session VI: TherapeuticsChair: Josh Frederick 
09:30 – 09:55mRNA-Based Approach For Treating Ischemic Heart DiseaseLior Zangi (Mt Sinai)
09:55 – 10:20Intratumoral interleukin-12 mRNA therapy promotes TH1 transformation of the tumor microenvironmentNadia Luheshi (AstraZeneca)
10:20 – 10:35Onco-selective Messenger RNAs For Cancer Cell-Specific Protein ExpressionYusuf Erkul (Kernal Biologics)
10:35 – 10:50In Vivo Bone Tissue Induction by Collagen-nanohydroxyapatite Matrix Loaded with BMP2/NS1 mRNAs LipopolyplexesChantal Pichon (CNRS Orléans)
10:50 – 11:05Intraventricular BDNF mRNA administration prevents ischemic neuronal death with the uptake predominantly by astrocytesYuta Fukushima (Tokyo Medical and Dental Univ)
11:05 – 11:30Break 
11:30 – 14:45Session VII: Pandemic Responses/COVID-19Chair: Norbert Pardi
11:30 – 11:50mRNA platform advances and COVID-19 candidate vaccinesNicholas Jackson (CEPI)
11:50 – 12:15The Moderna mRNA Vaccine Platform to Address SARS-CoV-2Jackie Miller (Moderna)
12:15 – 12:40BioNTech’s SARS-CoV-2 mRNA vaccinesUgur Sahin (BioNTech)
12:40 – 13:05Development of SARS-CoV-2 vaccine based on CureVac’s mRNA technologyLidia Oostvogels (CureVac)
13:05 – 13:15Break 
13:15 – 13:40Development of a self-amplifying RNA SARS-CoV-2 vaccine candidateRobin Shattock (Imperial College, London)
13:40 – 14:05LUNAR®-COV19: The Arcturus Therapeutics SARS-CoV-2 mRNA Vaccine CandidateSean Sullivan (Arcturus Therapeutics)
14:05 – 14:25The Innovative Medicines Initiative: Responding to COVID-19 through a public-private partnershipPierre Meulien (Innovative Medicines Initiative)
14:25 – 14:45Break 
14:45 – 16:15Session VIII: Regulatory Considerations
Chair: Charbel Haber
14:45 – 15:00The Regulatory Landscape for mRNA Vaccines:  A U.S. PerspectiveNorman W. Baylor (Biologics Consulting)
15:00 – 15:15Regulatory Considerations Specific to mRNA-based SARS-CoV-2 VaccinesMichael Pfleiderer (Biopharma Excellence)
15:15 – 16:15Round Table Discussion with Drs. Baylor and Pfleiderer, and Regulatory Heads Charbel Haber from Moderna, John Talian from CureVac and Andreas Kuhn from BioNTechNorman W. Baylor (Biologics Consulting), Michael Pfleiderer (Biopharma Excellence), John Talian (CureVac), Charbel Haber (Moderna), Andreas Kuhn (BionTech)
16:15 – 16:30Closing and passing of the batonOrganizing Committee

If you would like to stay updated on the details of the event, please sign up for our


Click here for our privacy policy.



The entire program of the mRNA Conference

My Agenda

Add lectures with the ★ to "My Agenda" and create your personal program for the conference


See all speakers of the mRNA Conference


Find out about all the sponsors of the mRNA conference.


Search for your participating colleagues and get in touch with them

Contact Exchange

Exchange your contact details with other attendees of the conference


Use the messenger to chat with your colleagues

Contact QR Code

Your QR Code for the selfprint station and admission control


Stay up to date and follow mRNA Conference on twitter


All important news of the mRNA Conference


Important information regarding the mRNA Conference

My Photo

Add a photo to your account

Data Consent

Change your data consent at any time